logo
Plus   Neg
Share
Email

PennyMac Mortgage Investment Trust Prices Common Share Offering

PennyMac Mortgage Investment Trust (PMT) said Tuesday that it has priced an underwritten public offering of 10 million common shares of beneficial interest.

The underwriters have a 30-day option from the date of the offering to purchase up to an additional 1.5 million shares from the company.

Settlement of the offering is expected to occur on May 11.

The company plans to use the net proceeds from the offering to fund a portion of the purchase price for two portfolios of residential whole mortgage loans, if such acquisitions are completed, to fund the continued growth of its correspondent lending business, to acquire additional mortgage loans or other investments, including those under existing forward purchase agreements, and for general corporate purposes.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT